Home

Pivotal bioVenture Partners Fund I U.G.P. Ltd

CIK 1752847 · last filed 2025-11-12

Pivotal bioVenture Partners Fund I U.G.P. Ltd is a corporate insider who has filed 4 SEC Form 4 insider transactions across 1 company since 2020. Across all open-market trades the lifetime net is +$32.8M, making them a net buyer over the disclosed history. The firm reports its address in San Francisco, CA. 8 SEC filings were submitted jointly with Pivotal bioVenture Partners Fund I, L.P.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

4

Lifetime Open-Market Net

$32.84M

Filer Profile

Reported Address
501 SECOND STREET, SUITE 200
SAN FRANCISCO, CA 94107
Phone
(415) 697-1002
State of Incorporation
Cayman Islands
Formerly Known As
Pivotal bioVenture Partners Fund I U.G.P., Ltd (2018–2023)
Related Filers
Pivotal bioVenture Partners Fund I, L.P. — 8 joint filings, latest 2025-11-12
Inozyme Pharma, Inc. — 4 joint filings, latest 2023-08-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Inozyme Pharma, Inc. (INZY) Delisted Director 1,571,741 $4.00 $6.29M $32.84M 3 2023-08-03

Recent Filings

4 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-11-12 — Conv (C) +10,103,925 $0
2023-08-03 Inozyme Pharma, Inc. (INZY) Delisted Buy (P) +2,499,999 $12.00M EDGAR
2022-04-20 Inozyme Pharma, Inc. (INZY) Delisted Buy (P) +3,210,000 $11.84M EDGAR
2020-07-28 Inozyme Pharma, Inc. (INZY) Delisted Mixed +4,773,462 $9.00M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.